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0959-8049/ª 2020 Elsevier Ltd. All righAbstract Background: This is the first national study on trends in cancer incidence for chil-
dren and young adolescents in the Netherlands, including stage at diagnosis as a potential
marker of early diagnosis and better staging.
Methods: All neoplasms in patients younger than 18 years, diagnosed between 1990 and 2017
(N Z 15,233), were derived from the Netherlands Cancer Registry. Incidence rates and the
average annual percentage change with 95% CIs were calculated for all cancers combined
and diagnostic (sub)groups. The stability of trends was examined by joinpoint analyses. Poten-
tial changes in early detection or improved staging over time were evaluated through propor-
tional alterations in stage at diagnosis.
Results: The annual overall cancer incidence increased significantly over time by 0.6% (95% CI
0.3e0.8) from 144 per million person-years in 1990e1999 to 162 in 2010e2017 and was sig-
nificant for both boys (þ0.5%, 0.2e0.8) and girls (þ0.7%, 0.3e1.1), for infants (aged 0 years;
þ1.5%, 0.4e2.5), teenagers (aged 10e14 years; þ0.6%, 0.3e1.0) and young adolescents (aged
15e17 years; þ0.7%, 0.2e1.2), with no trend interruptions. The incidence of leukaemia
(þ0.7%, 0.3e1.2), malignant CNS tumours including pilocytic astrocytomas (þ1.0%, 0.5
e1.5), neuroblastoma (þ1.2%, 0.1e2.2) and Ewing bone tumours (þ2.4%, 0.9e4.0) increased




A.M.J. Reedijk et al. / European Journal of Cancer 134 (2020) 115e126116leukaemia, in pilocytic astrocytoma and malignant melanoma. The proportion of early-stage
disease increased in patients with testicular germ cell tumours (þ21%) and malignant mela-
nomas (þ14%), whereas stage migration towards advanced disease was seen for Hodgkin lym-
phomas, soft tissue sarcomas and medullary thyroid carcinomas.
Conclusion: The increasing childhood cancer incidence could not be explained by a rise in
early diagnosis, which suggests that background risk factors seem of more importance.
ª 2020 Elsevier Ltd. All rights reserved.1. Introduction
The incidence of childhood cancer is increasing over
time in Europe [1]. Fortunately, survival of childhood
cancer improved from about 40% in the 1960s to nearly
80% nowadays [2,3]. However, cancer is still one of the
leading causes of death in children and adolescents [4].
In a recent analysis of data from 19 European coun-
tries, incidence trends of three common diagnostic
groups of childhood cancer were studied [1]. Increasing
incidence was observed for leukaemia in both children
and adolescents (þ0.7% and þ0.9% per year, respec-
tively), lymphoma in adolescents (þ1.0% per year) and
malignant tumours of the central nervous system (CNS)
in children (þ0.5% per year). Those increases are gener-
ally attributed to improved diagnostics and registration
practices, and/or changes in the prevalence of risk factors
[1,5]. New and improved methods for cancer diagnosis
are often more precise and may result in earlier diagnosis
and even more diagnosis of indolent cancers or cancers
with a bad prognosis previously not diagnosed during a
patient’s lifetime. More precise diagnostics may also lead
to an increase in the occurrence of advanced-stage disease
resulting in the so-called stage-migration. Therefore, in-
formation on stage at diagnosis could be useful to un-
derstand trends in incidence.
In the Netherlands, since 2002, young adolescents
until the age of 18 years are usually treated in paediatric
oncology centres as in many other European countries
[6]. Until now, no comprehensive national trend ana-
lyses on incidence of childhood cancer for the
Netherlands have been performed. The incidence of
childhood cancer has been only described for the ages
0e14 years in the South of the Netherlands until 1999.
In this study, an increasing incidence trend (þ3% per
year) was observed until 1997 and this flattened out
afterwards [7]. Therefore, an up-to-date population-
based estimation of the incidence of childhood cancer,
including young adolescents, is needed.
In this present study, we evaluate incidence trends of
cancer in children and young adolescents aged below 18
years and potential changes in early detection and
staging through proportional alteration in disease stage
at diagnosis in the Netherlands between 1990 and 2017
using population-based data of the Netherlands Cancer
Registry (NCR).2. Patients and methods
2.1. Data collection
Data on all malignant neoplasms in patients younger
than 18 years, diagnosed between 1990 and 2017, were
derived from the NCR, a nationwide population-based
cancer registry since 1989. The NCR is based on notifi-
cation of all newly diagnosed malignancies in the
Netherlands by the automated national pathological
archive PALGA with additional reporting by hospital
discharge registries and the haematology departments.
After notification, trained registration personnel
collect relevant information from medical records at the
hospitals. Since 2000, benign and borderline tumours of
the CNS (ICD-O-3, behaviour codes/0 and/1) are
included in the NCR. Those tumours were taken into
account in Figs. 1 and 2 only, to give a comprehensive
overview of all childhood cancers. Pilocytic astrocytomas
(ICD-O-3 M9421/1) were completely registered for the
period 1990e2017 and therefore included in all analyses.
Several other neoplasms were excluded because of
incomplete registration during the study period: myelo-
dysplastic syndromes (ICD-O-3 M codes starting with
998, registered since 2001, N Z 94), myeloproliferative
neoplasms (ICD-O-3 M9950-9962, registered since 2001,
NZ 26), Langerhans cell histiocytosis (ICD-O-3 M9750-
9754, not consistently registered before 2012, N Z 152),
carcinoid tumour of the appendix (ICD-O-3 site code
C18.1, M8240-M8249, before 2013 not consistently
registered as/3, N Z 221). Well-differentiated chon-
drosarcomas (ICD-O-3 M9220/31, N Z 28) and derma-
tofibrosarcomas (ICD-O-3 M8832, N Z 74) were also
excluded as they are classified as borderline neoplasms in
the newest ICD-O classification (ICD-O-3.2).
Neoplasms were categorised according to the Inter-
national Classification of Childhood Cancer (ICCC,
third edition) [8]. The stage was classified using the Ann
Arbor staging system for lymphomas [9], TNM classifi-
cation or the extent of disease (i.e. localised, regional and
distant) for other solid tumours [10]. Early-stage disease
at diagnosis was defined as Ann Arbor stage I for lym-
phomas, and as localised disease for other solid tumours
defined by the Toronto Paediatric Cancer Staging
guidelines [11]. Early-stage disease of malignant mela-
nomas and thyroid carcinomas are not defined by the
Fig. 1. Relative frequencies (in %) of diagnostic (sub)groups according to the International Classification of Childhood Cancer (ICCC)-3
classification [including benign and borderline central nervous system (CNS) tumours] by age group in children and young adolescents in
the Netherlands, 2000e2017 (Source: The Netherlands Cancer Registry).
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fication: M0/X for papillary/follicular, T1-4 N0/X M0/X
for medullary thyroid carcinomas and T1-2 N0/X M0/X
for malignant melanomas (Table S1). For astrocytomas
(i.e. ICCC-3 diagnostic subgroup IIIb), the degree of
malignancy, WHO grade was used [36]. WHO grade was
derived from the sixth digit of the ICD-O morphology
code and cross-checked with the first four digits of the
morphology code. In case of discrepancies, registry files
were checked by one of the authors (OV). Low degree of
malignancy was defined as WHO grade I/II.
2.2. Statistical analyses
Descriptive analysis of the average number per year and
proportions of diagnosis by ICCC-3 diagnostic groups
and main subgroups was performed. Incidence was
calculated as the average annual number of cases per
million person-years. Age-standardised incidence rates
(ASR) were calculated for the age group 0e17 years
using the weights of the world standard population [12],
and age-specific incidence rates were given to the age
groups: 0, 1e4, 5e9, 10e14 and 15e17 years. Incidence
rates were presented in the figures as three-year moving
averages by taking the average of the rates of each given
year and the rates either side of it. The study period was
divided into three periods: 1990e1999, 2000e2009 and
2010e2017.
Changes in incidence over time were evaluated by
calculating the average annual percentage change(AAPC) and corresponding 95% confidence interval (CI)
calculated for the period 1990e2017. AAPC was esti-
mated from a regression line that was fitted to the natural
logarithm of the rates using the calendar year as a re-
gressor variable and calculated for the period 1990e2017
[13]. The null hypothesis corresponds to no change in the
annual rate during the study period, which was equiva-
lent to 0 lying within the 95% CI of the AAPC. Benign
and borderline CNS tumours were not taken into ac-
count in those trend analyses, and trends were separately
described for the period 2000e2017 in Table S2. Join-
point regression program (version 4.5.0.1) was used to
check for trend transitions during the study period
[14,15]. The null hypothesis assumed that the AAPC was
constant throughout the study period. The permutation
test [15] was used to determine the number of joinpoints,
by default set to a maximum of four. For each detected
joinpoint, the AAPC and corresponding 95% CIs were
reported for each of the linear segments identified prior
and next to the detected joinpoint. AAPC and joinpoint
analyses were performed for all cancers combined and by
gender, age, diagnostic groups and main subgroups.
To determine changes in disease stage at diagnosis,
proportional alterations in all stages and early stage
versus advanced stage over time were evaluated and
tested by c2 test for each diagnostic group, except for
group I. Leukaemias and group XII. Other and un-
specified tumours. Unknown stages were excluded for
this analysis (N Z 767, 8% of the total included cancer
diagnosis, Table S1).
Fig. 2. Incidence of childhood and adolescent cancer by gender and
age (including benign and borderline CNS tumours) in the
Netherlands, 2000e2017 (Source: The Netherlands Cancer Regis-
try). A) Average number of new cases per year by gender and age. In
total, on average, 579 children and young adolescents were diag-
nosed with cancer in theNetherlands annually. B) Incidence rates by
gender and age. Age-standardised rates were calculated for all, boys
and girls [12], and age-specific rates for the given age groups.
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3. Results
In total, 15,233 cancer diagnoses in children and young
adolescents were registered during 1990e2017, including
706 diagnoses of benign and borderline CNS tumours,
which were included in the NCR since 2000. For the
period 2000e2017, those CNS tumours comprised 7% of
all new cancer diagnoses, and almost 30% of all new
CNS cancer diagnoses. The proportion of benign and
borderline CNS tumours varied by age from 5% of all
new cancer diagnoses and 18% of all new CNS cancer
diagnoses in children aged below 10 years to 10% and
50% in young adolescents aged 15e17 years.
Fig. 1 describes the distribution of the different diag-
nostic childhood cancer groups during 2000e2017.
About one-third (34%) was diagnosed before the age of 5
years and 21% in the age range 15e17 years. The most
common cancer types among infants (0 years) wereleukaemia and neuroblastomas, including other periph-
eral nervous cell tumours, comprising 40% of all new
cancer diagnoses in infants. Leukaemia was the most
common type of cancer in children of 1e9 years (31% of
all new cancer diagnoses in this age group). Lymphoma
becamemore common from the age of 10 years: 21%of all
new cancer diagnosis in 10e17 years old compared to
<5% in children below 5 years. In the younger age, Bur-
kitt lymphoma was common, whereas Hodgkin lym-
phoma was more present at the older ages. Bone tumours
were also common in 10e17 years old patients, resulting
in about 10% of all new cancer diagnoses in this age
group. Epithelial cancers became an important group in
the age group of 15e17 years, comprising 16% of all new
cancer diagnoses in those young adolescents.
3.1. Cancer incidence
In the period 2000e2017, on average, 579 children and
young adolescents were diagnosed with cancer in the
Netherlands annually, including the benign and
borderline CNS tumours (Fig. 2A). The average ASR of
childhood cancer was 168 per million person-years
(Fig. 2B). The boys were slightly more affected than
girls with an M:F ratio of 1.2 (ASR was 180 per million
in boys versus 156 in girls). The average incidence rate
also differed by age group. Children aged 5e9 years had
the lowest incidence with 127 per million person-years,
followed by teenagers aged 10e14 years with 135 per
million. The highest incidence was observed in infants (0
years) with 230 per million person-years.
3.2. Cancer incidence trends over time
The average number of new cancer cases, ASR per
million person-years and AAPC by diagnostic (sub)
group in children and young adolescents (aged 0e17
years) are shown in Table 1. Benign and borderline CNS
tumours were not taken into account in these trend
analyses, but are separately presented in Table S2.
Childhood cancer incidence increased significantly over
time by 0.6% per year (95% CI 0.3e0.8) from 144 per
million person-years in 1990e1999 to 162 in 2010e2017,
and was seen in both sexes, in infants (aged 0 years),
teenagers (aged 10e14 years) and young adolescents
(aged 15e17 years; Table 1 and Fig. 3A and B). Sig-
nificant increases were observed for leukaemia (þ0.7%
per year, 95% CI 0.3e1.2), CNS tumours (þ1.0% per
year, 0.5e1.5), neuroblastoma (i.e. diagnostic subgroup
IVa; þ1.2% per year, 0.1e2.2) and Ewing bone tumours
(þ2.4% per year, 0.9e4.0). Evaluation of trend transi-
tions during the study period using joinpoint analysis
are shown in Table 2.
Incidence increases of leukaemia were observed in girls
(from 35 per million person-years in 1990e1999 to 44 in
2010e2017; a rise of 1.1% annually, 95% CI 0.4e1.8) and
in infants (from 31 in 1990e1999 to 50 in 2010e2017;
Table 1




Average number of new cases per year Average incidence rate per million person-yearsc AAPCd
(%)
95% CI
1990e2017 1990e2017 1990e1999 2000e2009 2010e2017 1990e2017 1990e1999 2000e2009 2010e2017
All cancers 14,527 519 481 538 542 152.7 144.2 154.1 161.5 0.6 0.3e0.8
Gender
Boys 8079 289 269 301 297 166.0 158.3 168.1 172.9 0.5 0.2e0.8
Girls 6448 230 211 237 245 138.8 129.5 139.4 149.7 0.7 0.3e1.1
Age (in years)
0 1099 39 36 40 42 208.8 184.8 207.4 240.5 1.5 0.4e2.5
1e4 4188 150 147 154 147 195.3 189.4 194.1 204.2 0.4 e0.1 to 0.8
5e9 3101 111 102 121 109 114.8 108.0 121.3 115.2 0.4 e0.2 to 0.9
10e14 3228 115 102 120 126 119.2 111.3 121.2 126.5 0.6 0.3e1.0
15e17 2911 104 94 103 118 178.4 168.0 175.3 195.2 0.7 0.2e1.2
All cancers without pilocytic astrocytomas 13,653 488 456 503 508 143.6 137.0 144.0 151.5 0.5 0.3e0.7
ICCC-3 diagnostic group
I. Leukaemia’s 4103 147 134 156 151 44.8 41.4 46.2 47.3 0.7 0.3e1.2
Ia. Lymphoid leukaemia’s 3189 114 105 122 115 35.0 32.6 36.3 36.3 0.6 0.1e1.1
Ib. Acute myeloid leukaemia’s 728 26 24 26 28 7.8 7.3 7.7 8.5 0.8 e0.1 to 1.7
Ic. Chronic myeloproliferative diseases 83 3 2 4 4 0.8 0.6 0.9 1.0 NA
Id & Ie. Other & unspecified leukaemias 103 4 3 4 5 1.2 0.9 1.2 1.4 NA
II. Lymphomas 2098 75 72 75 79 20.2 20.1 19.8 20.8 0.2 e0.3 to 0.8
IIa. Hodgkin lymphomas 1013 36 33 38 38 9.4 8.9 9.7 9.7 0.6 e0.3 to 1.4
IIb. Non-Hodgkin lymphomas 711 25 25 23 29 7.0 7.2 6.3 7.7 0.3 e0.7 to 1.4
IIc. Burkitt lymphomas 359 13 14 13 11 3.7 4.0 3.7 3.2 e0.8 e2.3 to 0.7
IId & IIe. Other & unspecified lymphomas 15 1 0 1 1 0.1 0.1 0.1 0.2 NA
III. CNStumoursa 2819 101 88 104 112 29.7 26.5 29.8 33.6 1.0 0.5e1.5
IIIa. Ependymomas and choroid plexus tumours 272 10 10 10 8 3.0 3.2 3.1 2.6 e1.0 e2.4 to 0.5
IIIb/d. Astrocytomas & gliomas 1727 62 51 66 70 17.9 15.2 18.5 20.4 1.3 0.7e1.9
Pilocytic astrocytomas (ICD-O-3 M9421) 874 31 25 36 34 9.1 7.3 10.1 10.1 1.8 0.8e2.8
Astrocytomas NOS (ICD-O-3 M9400 and 9430) 212 8 13 4 5 2.2 3.7 1.2 1.5 NA
Gliomas NOS (ICD-O-3 M9380) 265 9 2 11 17 2.8 0.6 3.2 5.0 NA
IIIc. Embryonal tumours 616 22 19 24 24 6.7 5.8 6.9 7.5 1.2 0.1e2.3
IIIe & IIIf. Other & unspecified CNS tumours 204 8 8 5 10 2.2 2.3 1.3 3.1 1.3 e1.5 to 4.1
III. CNS tumours without pilocytic astrocytomas 1945 69 64 69 78 20.6 19.2 19.7 23.5 0.7 0.1e1.4
IV. Neuroblastoma and other peripheral nervous cell tumours 689 25 22 26 26 8.2 7.4 8.2 9.2 1.0 0.1e2.0
IVa. Neuroblastoma 667 24 21 25 26 8.0 7.1 8.1 9.0 1.2 0.1e2.2
V. Retinoblastomab 341 12 13 11 13 6.9 7.2 6.1 7.5 e0.6 e2.6 to 1.4
VI. Renal tumours 723 26 26 27 24 8.5 8.4 8.7 8.3 e0.2 e1.4 to 1.0
VII. Hepatic tumours 175 6 6 7 5 2.0 1.9 2.3 1.7 1.3 e1.2 to 3.8
VIII. Bone tumours 895 32 28 35 34 8.5 7.7 9.0 8.9 0.8 e0.2 to 1.8
VIIIa. Osteosarcomas 437 16 15 17 15 4.1 4.0 4.3 3.8 e0.5 e2.2 to 1.1
VIIIb. Chondrosarcomas 21 1 1 1 1 0.2 0.2 0.2 0.2 NA
VIIIc. Ewing tumours 340 12 10 13 14 3.3 2.8 3.4 3.8 2.4 0.9e4.0
VIIId & VIIIe. Other & unspecified bone tumours 97 3 2 4 4 0.9 0.7 1.1 1.0 NA
IX. Soft tissue sarcomas 977 35 35 34 35 10.1 10.5 9.8 10.0 e0.6 e1.5 to 0.3
















































Table 1 (continued )
Total number
of cases
Average number of new cases per year Average incidence rate per million person-yearsc AAPCd
(%)
95% CI
1990e2017 1990e2017 1990e1999 2000e2009 2010e2017 1990e2017 1990e1999 2000e2009 2010e2017
IXa. Rhabdomyosarcomas 514 18 20 17 17 5.5 6.2 5.0 5.2 e1.2 e2.4 to e0.1
IXb & IXe. Other & unspecified soft tissue sarcomas 463 17 15 17 18 4.6 4.3 4.8 4.8 0.2 e1.0 to 1.4
X. Germ cell & gonadal tumours 727 26 27 24 27 7.3 7.9 6.5 7.6 e0.1 e1.0 to 0.8
Xa. Intracranial and intraspinal germ cell tumours 126 5 5 4 4 1.2 1.4 1.1 1.1 e1.0 e3.9 to 1.8
Xb. Extracranial and extragonadal germ cell tumours 138 5 5 4 6 1.7 1.7 1.4 2.0 1.4 e0.7 to 3.5
Xc. Gonadal germ cell tumours: testis 269 10 10 8 11 5.1 5.7 4.2 5.5 e0.8 e2.5 to 0.9
Xc. Gonadal germ cell tumours: ovary 154 6 5 6 6 3.0 3.0 3.0 2.8 0.4 e1.9 to 2.7
Xd & Xe. Other & unspecified gonadal tumours 40 1 2 2 1 0.4 0.4 0.4 0.2 NA
XI. Other epithelial tumours 942 34 29 38 35 8.9 8.0 9.7 9.0 0.9 e0.1 to1.9
XIb. Thyroid carcinomas 255 9 9 8 11 2.4 2.4 2.2 2.8 1.7 e0.5 to 4.0
XId. Malignant melanoma 414 15 12 18 14 3.9 3.3 4.8 3.6 1.1 e0.2 to 2.5
XIa, XIc, XIe & XIf. Other & unspecified epithelial tumours 273 10 9 11 10 2.6 2.3 2.8 2.6 0.3 e1.5 to 2.1
XII. Other and unspecified tumours 37 1 1 1 2 0.4 0.3 0.4 0.6 NA
NA, estimation of a reliable average annual percentage change was not possible because of N Z 0 in 1 incidence year.
AAPC, average annual percentage change; CI, confidence interval; CNS, central nervous system; ICCC, International Classification of Childhood Cancer.
a Including pilocytic astrocytomas, other CNS tumours having a behaviour code/0 and/1 and completely registered since 2000 only were
excluded and those tumours are separately described in Table S2.
b Numbers, rates and average annual percentage change calculated for 0e9 years old, only.
c Incidence rates were standardised following the World Standard Population [12]; age-specific incidence rates were calculated for age groups
consisting 5 years.

















































Fig. 3. Trends in incidence of childhood and adolescent cancer by gender and age in the Netherlands, 1990e2017 (Source: The
Netherlands Cancer Registry). A) Age-standardised incidence rates [12] by gender over time. B) Age-specific incidence rates by age group
over time. AAPC estimated from a regression line, which was fitted to the natural logarithm of the rates using calendar year as regressor
variable. Note: Benign and borderline CNS tumours were excluded. AAPC, Average Annual Percentage Change; CI, confidence interval.
A.M.J. Reedijk et al. / European Journal of Cancer 134 (2020) 115e126 121þ3.1% per year, 1.2e5.1), with no trend transitions.
Except for the boys, a temporary incidence increase was
seen during the time segment 1990e1997 by 4.8% per year
(95% CI 0.4e9.4) followed by a stable incidence at 52 per
million. In young adolescents, incidence tended to in-
crease by 1.4% per annum (95% CI e0.0 to 2.9), from 23
per million person-years in 1990e1999 to 29 in
2010e2017. Lymphoid leukaemia (LL) represented 77%
of all leukaemias and mainly responsible for the signifi-
cant increase of leukaemia (LL þ0.6% per year, 95% CI
0.1e1.1; Table 1). Incidence of three main types of lym-
phomas remained stable over time (Table 1).
Incidence increases of CNS tumours were seen in
both sexes with a rise of 1.0% per year (boys: from 28
per million person-years in 1990e1999 to 36 in
2010e2017; girls: from 25 in 1990e1999 to 32 in
2010e2017) and in young children below the age of 5
years with a rise of 1.3% annually (95% CI 0.5e2.0;
from 31 per million in 1990e1999 to 42 in 2010e2017),with no significant changes in trend (Table 2). The in-
crease of CNS tumours was caused by increases of as-
trocytomas/gliomas and embryonal CNS tumours
(þ1.3% annually, 95% CI 0.7e1.9 and þ1.2% per year,
0.1e2.3, respectively) comprising 83% of all CNS tu-
mours. Pilocytic astrocytomas represented half of the
astrocytomas/gliomas and partially responsible for the
significant increase in incidence of astrocytomas/gliomas
(þ1.8% per year, 95% CI 0.8e2.8; Table 1). In joinpoint
analysis, the trend of pilocytic astrocytomas increased
until 2010 by 3.4% per annum (95% CI 2.0e4.8) fol-
lowed by a stable incidence at 10 per million person-
years. The same pattern was visible in girls and 5e9
years old ones (Table 2). Simultaneously, a decline in
unspecified astrocytomas was observed from 3.7 per
million person-years in 1990e1999 to 1.5 in 2010e2017.
By contrast, unspecified gliomas increased from 0.7 per
million person-years in 1990e1999 to 5.0 in recent years.
Most of these cases were coded at the brain stem (ICD-
A.M.J. Reedijk et al. / European Journal of Cancer 134 (2020) 115e126122O-3 site C71.7; 79%) and were not microscopically
verified (82%). In the 1990s, unspecified gliomas of the
brain stem were also registered with morphology code
M8000, which declined over time from 0.6 per million
person-years in 1990e1999 to 0.1 in 2010e2017.
The incidence of neuroblastoma (i.e. diagnostic sub-
group IVa) has risen significantly from 7.1 per million
person-years in 1990e1999 to 9.0 in 2010e2017 with no
joinpoints. The increase of Ewing bone tumours was
observed in boys with a rise of 3% annually (95% CI
1.0e5.1), from 3.0 per million person-years in
1990e1999 to 4.1 in 2010e2017 with no trend transi-
tions (Table 2). The same pattern was seen in all tu-
mours of the Ewing sarcoma family (diagnostic
subgroups VIIIc and IXd.1-d.2), incidence increased by
2.3% (95% CI 0.8e3.7) from 3.4 per million person-
years in 1990e1999 to 4.8 in 2010e2017, mainly seenFig. 4. Time trends in stage at diagnosis by diagnostic ICCC-3 (sub)g
(aged 0e17 years) in the Netherlands, 1990e2017 (Source: The Nether
(sub)group are described in Table S1. Early-stage disease is highlighted
excluded. WHO, World Health Organisation.in boys in which the incidence rate rose to 5.3 in
2010e2017 (þ3% annually, 95% CI 0.9e5.1).
From the epithelial tumours, thyroid cancer seemed
to increase in young adolescents from 5.9 per million
person-years in 1990e1999 to 10 in 2010e2017 (þ3%
per annum, 95% CI e0.2 to 6.2). A temporary increase
in the incidence of malignant melanomas was observed
during 1990e2002 by þ6.5% per year (95% CI 2.7e11),
and tended to decrease afterwards by e2.5% per year
(e5.0 to 1.0; Table 2).
3.3. Changes in stage at diagnosis over time
Time trends in stage at diagnosis by diagnostic (sub)
group in children and young adolescents are presented
in Fig. 4. Shifts in stage were observed for Hodgkin
lymphoma, non-rhabdomyosarcomas, testicular germroups and period of diagnosis in children and young adolescents
lands Cancer Registry). Staging criteria of each ICCC-3 diagnostic
in orange shades. Note: Benign and borderline astrocytomas were
Table 2
Trends in incidence of cancer in children and young adolescents (aged 0e17 years) for the entire study period and for any time segment identified
in joinpoint analysis by diagnostic ICCC-3 (sub)group, gender and age at diagnosis in the Netherlands, 1990e2017a,b.









Overall trend AAPC during a time segment (95% CI) identified by joinpoint analysis 
 AAPC, % (95% CI) Year of incidence 
   1990     1995     2000     2005     2010     2015   
I. Leukaemia’s 147 44.8 0.7 (0.3 to 1.2)                              
 Gender                                
   Boys 85 50.2 0.5 (-0.1 to 1.1) 4.8 (0.4 to 9.4) -0.4 (-1.3 to 0.5) 
   Girls 62 39.1 1.1 (0.4 to 1.8)                             
 Age (in years)                                
   0 8 42.8 3.1 (1.2 to 5.1)                             
   1-4 62 81.3 0.4 (-0.2 to 1.1)                             
   5-9 36 37.4 0.6 (-0.2 to 1.4)                             
   10-14 26 26.3 0.6 (-0.5 to 1.6)                             
   15-17 15 25.1 1.4 (-0.0 to 2.9)                             
III. CNS tumours 101 29.7 1.0 (0.5 to 1.5)                             
 Gender                                
   Boys 55 31.5 1.0 (0.4 to 1.7)                             
   Girls 46 27.8 1.0 (0.2 to 1.9)                             
 Age (in years)                                
 <5 33 35.1 1.3 (0.5 to 2.0)                             
   5-9 31 32.5 0.9 (-0.3 to 2.1)                             
   10-14 24 24.4 0.3 (-0.8 to 1.4)                             
   15-17 12 21.1 1.2 (-0.4 to 2.7)                             
IIIb. Pilocytic astrocytomas 31 9.1 1.8 (0.8 to 2.8)  3.4 (2.0 to 4.8) -5.5 (-11.7 to 1.0) 
 Gender                                
   Boys 15 8.7 1.5 (0.3 to 2.8)                             
   Girls 16 9.5 1.9 (0.2 to 3.6) 4.2 (2.0 to 6.5) -11.6 (-23.5 to 2.1) 
 Age (in years)                                
 <5 9 9.6 2.3 (0.6 to 4.1)                             
   5-9 11 10.9 1.0 (-0.7 to 2.7) 4.4 (2.0 to 6.9) -10.0 (-17.4 to -1.8) 
   10-14 7 7.7 0.7 (-0.9 to 2.3)                             
   15-17 4 7.0 NA                             
IVa. Neuroblastomas 24 8.0 1.2 (0.1 to 2.2)                             
 Gender                                
   Boys 13 8.8 1.1 (-0.2 to 2.4)                             
   Girls 11 7.7 1.0 (-0.6 to 2.7)                             
 Age (in years)                                
   0 8 42.7 0.6 (-1.1 to 2.3)                             
1-4 12 16.3 1.3 (-0.1 to 2.7)
5-17 4 1.7 1.9 (-0.6 to 4.4)
VIIIc. Ewing bone tumours 12 3.3 2.4 (0.9 to 4.0)
Gender
Boys 7 3.6 3.0 (1.0 to 5.1)
Girls 5 3.0 2.1 (-0.5 to 4.7)
Age (in years)
<10 4 2.0 NA
10-17 8 5.3 NA
IXa. Rhabdomyosarcomas 18 5.5 -1.2 (-2.4 to -0.1)
Gender
Boys 11 6.3 -1.2 (-3.1 to 0.6)
Girls 8 4.7 -1.4 (-2.9 to 0.1)
Age (in years)
<5 8 8.0 -1.9 (-4.2 to 0.3)
5-9 5 5.0 -0.4 (-2.4 to 1.5)
10-17 6 3.7 -0.4 (-2.4 to 1.5)
XId. Malignant melanomas 15 3.9 1.1 (-0.2 to 2.5) 6.5 (2.7 to 10.5) -2.5 (-5.0 to 0.1)
Gender
Boys 6 3.1 2.1 (-0.7 to 5.0)
Girls 9 4.8 0.7 (-1.1 to 2.4)
Age (in years)
<15 7 2.2 NA
15-17 8 13.9 -0.3 (-1.7 to 1.1)
NA: joinpoint analysis and estimation of a reliable average annual percentage change was not possible because of N=0 in ≥1 incidence years
Significant increasing trend in the incidence is highlighted in orange, and significant decreasing trend is highlighted in green. 
a No trend transitions were observed for the total group
bJoinpoint analyses were also performed for II. Lymphomas, IIIc. Embryonal tumours, V. Retinoblastomas, VI. Renal tumours, VII. Hepatic tumours, VIII. Bone tumours, IX. Soft tissue sarcomas,
X. Germ cell and gonadal tumours and XI. Other epithelial tumours, but no significant changes in incidence were found during the entire study period or during any time segment.
c Incidence rates were standardised following the World Standard Population [13]; age-specific incidence rates were calculated for age groups consisting ≤ 5 years
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nant melanomas. For testicular germ cell tumours and
malignant melanomas, early-stage disease increased
over time: stage I testicular germ cell tumours rose from
55% in 1990e2009 to 76% in 2010e2017 (pZ 0.01), and
stage I melanomas showed a rise from 48% in
1990e1999 to 62% in 2000e2017 (p Z 0.047). The de-
gree of malignancy in astrocytomas shifted towards
WHO grade I and increased from 51% in 1990e1999 to
67% in 2010e2017 (p < 0.001).A shift to more advanced disease at diagnosis was
seen in Hodgkin lymphomas, rhabdomyosarcomas,
non-rhabdomyosarcomas and medullary thyroid carci-
nomas. Hodgkin’s Ann Arbor I declined from 18% in
1990e1999 to 8% in 2010e2017 (p Z 0.002) mainly due
to an increase in Ann Arbor IV. Early-stage disease of
rhabdomyosarcomas slightly decreased from 83% in
1990e1999 to 73% in 2010e2017 (p Z 0.05) mainly due
to a decrease in stage II/III and a rise in stage IV. The
same pattern was observed in non-rhabdomyosarcomas
A.M.J. Reedijk et al. / European Journal of Cancer 134 (2020) 115e126124(from 90% to 79%, p Z 0.02) due to an increase in
metastatic disease. Localised medullary thyroid carci-
noma declined from 93% in 1990e1999 to 64% in
2010e2017 (p Z 0.01), whereas regional and metastatic
disease increased (Fig. 4).4. Discussion
This is the first nationwide, population-based study on
time trends in incidence of childhood and young
adolescent cancer in the Netherlands. Over a 28-year
period, the overall cancer incidence increased by an
average of þ0.6% annually. This increase in incidence
was especially seen in infants, teenagers and young ad-
olescents, and in the diagnostic (sub)groups: leukaemia,
malignant CNS tumours, neuroblastoma and Ewing
sarcoma. Rise in early-stage disease was seen in testic-
ular germ cell tumours and malignant melanomas only,
whereas a stage migration to more advanced stages was
observed for Hodgkin lymphomas, soft tissue
sarcomas and medullary thyroid carcinomas.
The slight increase in the overall cancer incidence
since the 1990s is in line with a recent international
pooling of European data, which showed an average
increase of þ0.5% per year in children younger than 15
years, and þ1.0% in adolescents (aged 15e19 years)
during 1991e2010 [1]. A steady rise in cancer incidence
among children has been seen in the developed countries
since the 1950s [2,16]. Reasons for this rise are difficult
to pin down as changes in diagnostic procedures and
imaging, but also in registry procedures have taken
place, and the aetiology of cancer in children is still
largely unknown [2,17].
Advances in diagnostic technology may result in an
increased (earlier) detection and/or stage migration. In
this study, increased detection was observed for low-
grade pilocytic astrocytomas until 2010, especially in
young children (<10 years), which partly caused the
total increase of CNS tumours. This finding is a result of
a shift from unspecified astrocytomas towards pilocytic
astrocytomas and most likely due to an increasing use of
magnetic resonance imaging (MRI). This is consistent
with a study from Great Britain in the 1990s [17],
although the incidence increase started later in the
Netherlands. Probably, the rise in unspecified gliomas at
the brain stem is partially also due to the increased use
of MRI. Simultaneously, a rise in high-grade embryonal
CNS tumours was observed. This might be a result of
increasing use of molecular diagnostic tools combined
with a higher diagnostic awareness of atypical teratoid/
rhabdoid tumours because its recognition as a distinct
pathologic entity since the mid-1990s [18]. However, in
other countries, a simultaneous decreasing trend for
unspecified embryonal CNS tumours was detected and
even a decreasing trend for medulloblastomas [19e21].
In this study, detailed trend analyses of the subtypeswere not performed and therefore the exact cause of the
observed rise in embryonal CNS tumours remains
unclear.
Stage migration towards advanced-stage disease as a
result of improved and more precise diagnostics was
seen in Hodgkin lymphomas, soft tissue sarcomas and
medullary thyroid carcinomas (MTC). However, these
changes did not result into an increasing incidence [23]
For MTCs even a lower incidence was observed which
might be the result of prophylactic surgery for multiple
endocrine neoplasia 2a and 2b. Since 1993, genetic
screening has been introduced in the Netherlands to
identify carriers of these syndromes to prevent MTC by
early prophylactic thyroid surgery which resulted in
more frequent findings of thyroids with C-cell hyper-
plasia instead of MTC [37,38]. This might also explain
the stage shift in MTCs. The opposite, an increased
proportion of early-stage disease, was observed in
malignant melanomas and testicular germ cell tumours.
For melanomas, this is due to the increased diagnostic
awareness among general practitioners, dermatologists
and the general population as a result of prevention
campaigns [24]. Causes for the rise in early disease of
testicular germ cell tumours is less clear and probably a
mix of increased diagnostic awareness among general
practitioners and the use of more sensitive imaging
modalities [25].
The effect of improved diagnostics and diagnostic
awareness on the rising incidences of leukaemia, neu-
roblastoma and Ewing tumours is less clear. The largest
increase of leukaemia was made during the 1990s and
most visible in infants. Under-diagnosis in the past
could be a reason as shown in a study from the United
Kingdom, where acute lymphoblastic leukaemia was
under-diagnosed in poorer communities [26]. However,
this seems not valid for our finding as the Netherlands
has a high-quality system of child health care. Over 90%
of all children up to the age of 4 years visit the free
public service of child health clinics that monitor health
and social development on a regular basis [27]. A recent
publication of our group showed that the rising inci-
dence of neuroblastoma could not be explained by
registration artefacts, immigration of paediatric patients
to the Netherlands or improved diagnostics [28]. For the
observed increase in Ewing tumours, we do not expect
that diagnostics play a role. Despite of the difficulty in
interpretation of biopsy specimens, a pathology review
in the Netherlands showed that agreement on original
diagnosis was almost perfect for Ewing tumours [29].
The possibility of real changes in background risk
factors cannot be excluded as a cause of the observed
increasing childhood cancer incidence. Etiological fac-
tors are largely unknown for most childhood cancers,
but changes in social structures (e.g. older maternal age,
increasing percentage of Caesarean deliveries, birth
weight, family size, attitudes regarding breastfeeding
and immunisation, daycare attendance), socioeconomic
A.M.J. Reedijk et al. / European Journal of Cancer 134 (2020) 115e126 125situation, exposure to artificial and natural substances
(e.g. ionising radiation, electromagnetic fields, pesti-
cides, etc.) during the last decades might have some
impact on the development of childhood cancer
[1,2,30e33]. Most of those risk factors have been asso-
ciated with leukaemia [34].
The strength of our study was its population-based
nature and the NCR not having age or hospital limits
(i.e. inclusion of children and young adolescents who
might not have been treated by a paediatric oncologist).
In a previous study, we have linked the NCR with the
Registry of the Dutch Childhood Oncology Group,
which showed that 18% of children and adolescents with
cancer below the age of 18 years were not known in
paediatric oncology centres [6]. A limitation of this
study is the missing stage information of ependymomas
and embryonal CNS tumours as the Toronto staging
guidelines were implemented in the NCR since 2018.
Furthermore, there were changes in stage registration
over time: during 1990e2002, TNM classification was
used for blastomas, whereas since 2003, the extent of
disease was used. However, it was possible to generate
stage categories based on both staging classifications
(Table S1), and the distribution of stages was in line with
a population-based study from Australia, which
described the distribution of cases by stage at diagnosis
for the first time [35]. Moreover, we have tried to
minimise the influence of registration artefacts by
excluding those tumours that were not registered
completely during our study period.5. Conclusion
In conclusion, this is the first study that describes the
incidence for children and young adolescents in the
Netherlands including the unique information on stage
at diagnosis. Rise in early-stage disease was found for a
few childhood cancers only, but could not explain the
total increase in cancer incidence. Improved diagnostics
and increased diagnostic awareness have mainly led to
higher proportions of advanced disease. Real changes in
background factors seem of more importance in
explaining the incidence increase.Funding
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